Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Total Liabilities (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Total Liabilities for 5 consecutive years, with $114.2 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 4.36% to $114.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $114.2 million through Dec 2025, up 4.36% year-over-year, with the annual reading at $114.2 million for FY2025, 4.36% up from the prior year.
  • Total Liabilities hit $114.2 million in Q4 2025 for Krystal Biotech, up from $102.2 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $114.2 million in Q4 2025 to a low of $12.4 million in Q1 2021.
  • Historically, Total Liabilities has averaged $59.3 million across 5 years, with a median of $42.6 million in 2021.
  • Biggest five-year swings in Total Liabilities: soared 452.48% in 2022 and later tumbled 38.11% in 2023.
  • Year by year, Total Liabilities stood at $32.7 million in 2021, then grew by 10.7% to $36.2 million in 2022, then rose by 9.65% to $39.7 million in 2023, then soared by 175.62% to $109.5 million in 2024, then increased by 4.36% to $114.2 million in 2025.
  • Business Quant data shows Total Liabilities for KRYS at $114.2 million in Q4 2025, $102.2 million in Q3 2025, and $97.7 million in Q2 2025.